Unknown PHASE3 INTERVENTIONAL 2-arm NCT04034199

Treating Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density With Denosumab or Zoledronic Acid

Efficacy of Denosumab and Zoledronic Acid in the Treatment of Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density: a Prospective Controlled Trial

Sponsor: Kwong Wah Hospital

Conditions Idiopathic Inflammatory Myopathies Osteoporosis, Osteopenia

Interventions Denosumab Zoledronic Acid

Updated 5 times since 2019 Last updated: Jul 23, 2019 Started: Aug 15, 2019 Primary completion: Dec 31, 2020 Completion: Mar 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Idiopathic Inflammatory Myopathies and Osteoporosis, Osteopenia and is currently ongoing. Kwong Wah Hospital leads this study, which shows 5 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE3

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Not Yet Recruiting PHASE3
Aug 2019 — Jan 2021 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kwong Wah Hospital
Tung Wah Group of Hospitals

Data source: Kwong Wah Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hong Kong, Hong Kong